Modification of HEART Pathway for Patients With Chest Pain: A Korean Perspective

Bora Chae1, Shin Ahn2, Youn-Jung Kim1

  • 1Department of Emergency Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Korean Circulation Journal
|September 1, 2023
PubMed

Insights

The modified HEART pathway accurately identifies low-risk chest pain patients for early discharge. This revised pathway, using a higher obesity threshold, improved MACE identification in a Korean population.

Area of Science:

  • Cardiology
  • Emergency Medicine
  • Clinical Risk Stratification

Background:

  • The HEART pathway aids in identifying low-risk patients with chest pain.
  • Accurate risk stratification is crucial for timely emergency department discharge.

Purpose of the Study:

  • To modify and evaluate the HEART pathway for chest pain patients in a Korean population.
  • To assess the impact of adjusting the obesity BMI threshold on MACE risk identification.

Main Methods:

  • Prospective enrollment of 1,304 chest pain patients.
  • Modification of the HEART pathway using a 30 kg/m² obesity threshold instead of 25 kg/m².
  • Primary outcome: Major Adverse Cardiac Event (MACE) within 30 days.

Main Results:

  • The modified HEART pathway identified 37.3% of patients as low-risk.
  • A lower incidence of MACE was observed in the low-risk group identified by the modified pathway (0.8% vs 1.6%).
  • The modified pathway demonstrated high sensitivity (98.8%) and NPV (99.2%) for MACE detection.

Conclusions:

  • The modified HEART pathway, utilizing Korean-specific BMI cut-offs, enhances the accurate identification of low-risk patients.
  • This adaptation facilitates safer and more precise early discharge decisions for chest pain patients in Korea.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
18
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19